Phaseline

Targets › PDGFRA

PDGFRA (Platelet-derived growth factor receptor alpha): drug programs, companies and trials

32 programs from 31 companies in 125 trials: 61 Phase 2, 44 Phase 1, 19 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Respiratory; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. (UniProt, P16234)

Open in Phaseline: the race on PDGFRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Blueprint MedicinesAvapritinib (BLU-285)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 4Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 …Jun 2027
Gossamer Bio USASeralutinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor
KIT, PDGFRB, PDGFRA, CSF1RPhase 3Pulmonary Arterial HypertensionDec 2026
Deciphera PharmaceuticalsVimseltinib (DCC-3014)
KIT/PDGFRA/CSF1R inhibitor
CSF1R, KIT, PDGFRAPhase 3Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants …Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Deciphera PharmaceuticalsRipretinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 3GIST; Gastrointestinal Stromal TumorsMar 2027
Daiichi SankyoQuizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
Jiangsu HengRui MedicineFamitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
GSKIDRX-42 (GSK6042981, velzatinib)
Receptor tyrosine kinase inhibitor
KIT, PDGFRAPhase 3Gastrointestinal Neoplasms; Gastrointestinal Stromal NeoplasmsNov 2027
AB ScienceMasitinib
Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FGFR3, KIT, PDGFRB, PDGFRAPhase 3Amyotrophic Lateral SclerosisDec 2027
Cogent BiosciencesCGT9486
FIP1L1-PDGFRα inhibitor
PDGFRAPhase 3Advanced Gastrointestinal Stromal TumorsJan 2030
M.D. Anderson Cancer CenterSunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate CancerDec 2026
National Cancer Institute (NCI)Sunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine TumorDec 2026
Avalyn PharmaNintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
Beijing Scitech-Mq PharmaceuticalsST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026
Sun Yat-sen UniversityAnlotinib Hydrochloride
Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET
VEGFR, PDGFRA, PDGFRB, FLT1, KITPhase 2GlioblastomaDec 2026
Canadian Cancer Trials GroupSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Rare TumoursDec 2026
University of MiamiSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsDec 2026
Sarcoma Alliance for Research through CollaborationSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsJun 2027
Tianjin Medical University Cancer Institute and HospitalAnlotinib Hydrochloride
multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor)
KDR, PDGFRA, FLT4Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerJun 2027
Fudan UniversitySitravatinib
Small molecule inhibitor of receptor tyrosine kinases
PDGFRA, KIT, RET, FLT3Phase 2Metastatic Breast CancerJun 2027
MannkindNintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027
American Society of Clinical OncologySunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Lymphoma, Non-HodgkinDec 2027
Bai-Rong XiaSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Ovary CancerDec 2027
Memorial Sloan Kettering Cancer CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2OsteosarcomaMar 2028
NovartisMidostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029
AstraZenecacediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
Betta PharmaceuticalsX-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
State University of New York at BuffaloSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Carcinoma, Renal CellJul 2027
University of Colorado, DenverSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1OsteosarcomaAug 2027
Telix Pharmaceuticals (Innovations)89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
anti-PDGFRA antibody labeled with zirconium-89 for diagnostic imaging
PDGFRAPhase 1Soft Tissue SarcomaOct 2027
Rabin Medical CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Solid Tumors Refractory to Standard TherapyJan 2028
Ono PharmaceuticalRipretinib (DCC-2618)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 1Gastrointestinal Stromal TumorsFeb 2028

Conditions

Acute Myeloid Leukemia (9) Gastrointestinal Stromal Tumors (4) Colorectal Cancer (2) Hepatic Impairment (2) Renal Cell Carcinoma (RCC) (2) Pulmonary Arterial Hypertension (2) Osteosarcoma (2) Fallopian Tube Clear Cell Adenocarcinoma (2) Cervical Cancer (2) Fallopian Tube Carcinoma (2) TNBC - Triple-Negative Breast Cancer (2) GIST (2)

Modalities

small molecule (24), antibody (4), mixed (4)

Companies

Deciphera Pharmaceuticals (2) Beijing Scitech-Mq Pharmaceuticals (1) Canadian Cancer Trials Group (1) Novartis (1) Tianjin Medical University Cancer Institute and Hospital (1) Exelixis (1) Ono Pharmaceutical (1) Avalyn Pharma (1) Gossamer Bio USA (1) Blueprint Medicines (1) Fudan University (1) Telix Pharmaceuticals (Innovations) (1) Daiichi Sankyo (1) Mannkind (1) Sun Yat-sen University (1) Memorial Sloan Kettering Cancer Center (1) University of Colorado, Denver (1) AstraZeneca (1) Sarcoma Alliance for Research through Collaboration (1) Jiangsu HengRui Medicine (1)

Related targets

KIT (25) PDGFRB (21) FLT3 (15) CSF1R (14) FLT1 (6) FLT4 (5) KDR (4) MET (2) RET (2) FGFR3 (2) VEGFR2 (1) AXL (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.